NCT05345769 - Safety and Efficacy of AM712 in Patients with NAMD | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 28, 2022

Primary Completion Date

November 4, 2024

Study Completion Date

November 4, 2024

Conditions

Neovascular Age-related Macular Degeneration

Interventions

BIOLOGICAL

AM712(ASKG712)

AM712 is a recombinant anti-VEGF humanized monoclonal antibody and Ang-2 antagonist peptide fusion protein, which has high specificity for the binding of VEGF-A and Ang-2.

Trial Locations (9)

32901

Florida Eye Associates, Melbourne

37203

Tennessee Retina, PC, Nashville

77384

Retina Consultants of Texas, The Woodlands

77401

Retina Consultants of Texas, Bellaire

78240

Retina Consultants of Texas, San Antonio

80228

Colorado Retina, Lakewood

92064

Retina Consultants San Diego, Poway

94598

Bay Area Retina Associates, Walnut Creek

01107

Retina Research Institute at New England Retina Consultants, Springfield